PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment.
2/5 보강
OpenAlex 토픽 ·
Cancer, Lipids, and Metabolism
Lipoproteins and Cardiovascular Health
Cholesterol and Lipid Metabolism
[INTRODUCTION] Cholesterol plays critical roles in prostate cancer (PCa) proliferation, immune evasion, and androgen signaling.
- 표본수 (n) 18
APA
Yan Gu, Fengxiang Wei, et al. (2026). PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment.. Journal of advanced research. https://doi.org/10.1016/j.jare.2026.04.020
MLA
Yan Gu, et al.. "PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment.." Journal of advanced research, 2026.
PMID
41951051 ↗
Abstract 한글 요약
[INTRODUCTION] Cholesterol plays critical roles in prostate cancer (PCa) proliferation, immune evasion, and androgen signaling. PCSK9 regulates cholesterol metabolism. Its role in PCa remains unclear.
[OBJECTIVE] To investigate PCSK9's function in promoting PCa progression and the underlying mechanisms.
[METHODS] We utilized PCa stem cells (PCSC), primary and metastatic PCa, intact and castrated Pten mice, TRAMP mice, and xenografts produced in intact and castrated mice using LNCaP cells overexpressing empty vector (EV), PCSK9, gain-of-function (D374Y) and loss-of-function (Q152H) mutant. TRAMP/Pcsk9 mice were generated. The anti-PCSK9 antibody evolocumab was used. Androgen receptor (AR) signaling, angiogenesis, cholesterol accumulation, immune checkpoint (IC) expression, and CD8+ T cell infiltration were examined. RNA-seq was performed on xenografts. Differentially expressed genes and pathway alterations were evaluated.
[RESULTS] PCSK9 upregulation occurs in PCSC, intact and castrated prostate-specific Pten mice, primary, metastatic, and castration resistant PCa (CRPC). PCSK9 increased LNCaP tumor growth under intact and castrated conditions, and elevated intratumoral cholesterol, angiogenesis, nuclear AR, CYP17A1, and SRD5A1. Evolocumab treatment extended overall survival (OS) in TRAMP mice. TRAMP;Pcsk9 mice exhibited reduced tumor growth, metastasis, intratumoral cholesterol, CYP17A1, SRD5A1, ABI3, CORO1A, VISTA, CD53, enhanced CD8+ T cell infiltration and OS. ABI3, CORO1A, and CD53 are novel to PCa. ABI3 and CORO1A strongly correlate with CD53, VISTA, and multiple other ICs (n = 18) in 8 independent PCa populations, including metastases and CRPCs. ABI3 and CORO1A are among 15 immune-related genes (Sig15IM) upregulated by PCSK9. Sig15IM robustly stratifies PCa recurrence. In multiple single-cell RNA-seq datasets, Sig15IM, ABI3, ABI3corrgenes (ABI3 correlated genes), CORO1A, CORO1Acorrgenes, and CD53 are predominantly expressed or upregulated in exhausted CD8+ T and Treg in PCa and eight other cancer types.
[CONCLUSIONS] PCSK9 promotes PCa progression via enhancing intratumoral cholesterol accumulation and shaping immunosuppressive microenvironment involving novel immunosuppressive factors: Sig15IM, ABI3, CORO1A, ABI3corrgenes, CORO1Acorrgenes, and CD53. PCSK9 facilitates VISTA expression in PCa.
[OBJECTIVE] To investigate PCSK9's function in promoting PCa progression and the underlying mechanisms.
[METHODS] We utilized PCa stem cells (PCSC), primary and metastatic PCa, intact and castrated Pten mice, TRAMP mice, and xenografts produced in intact and castrated mice using LNCaP cells overexpressing empty vector (EV), PCSK9, gain-of-function (D374Y) and loss-of-function (Q152H) mutant. TRAMP/Pcsk9 mice were generated. The anti-PCSK9 antibody evolocumab was used. Androgen receptor (AR) signaling, angiogenesis, cholesterol accumulation, immune checkpoint (IC) expression, and CD8+ T cell infiltration were examined. RNA-seq was performed on xenografts. Differentially expressed genes and pathway alterations were evaluated.
[RESULTS] PCSK9 upregulation occurs in PCSC, intact and castrated prostate-specific Pten mice, primary, metastatic, and castration resistant PCa (CRPC). PCSK9 increased LNCaP tumor growth under intact and castrated conditions, and elevated intratumoral cholesterol, angiogenesis, nuclear AR, CYP17A1, and SRD5A1. Evolocumab treatment extended overall survival (OS) in TRAMP mice. TRAMP;Pcsk9 mice exhibited reduced tumor growth, metastasis, intratumoral cholesterol, CYP17A1, SRD5A1, ABI3, CORO1A, VISTA, CD53, enhanced CD8+ T cell infiltration and OS. ABI3, CORO1A, and CD53 are novel to PCa. ABI3 and CORO1A strongly correlate with CD53, VISTA, and multiple other ICs (n = 18) in 8 independent PCa populations, including metastases and CRPCs. ABI3 and CORO1A are among 15 immune-related genes (Sig15IM) upregulated by PCSK9. Sig15IM robustly stratifies PCa recurrence. In multiple single-cell RNA-seq datasets, Sig15IM, ABI3, ABI3corrgenes (ABI3 correlated genes), CORO1A, CORO1Acorrgenes, and CD53 are predominantly expressed or upregulated in exhausted CD8+ T and Treg in PCa and eight other cancer types.
[CONCLUSIONS] PCSK9 promotes PCa progression via enhancing intratumoral cholesterol accumulation and shaping immunosuppressive microenvironment involving novel immunosuppressive factors: Sig15IM, ABI3, CORO1A, ABI3corrgenes, CORO1Acorrgenes, and CD53. PCSK9 facilitates VISTA expression in PCa.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.
- The gut-liver axis modulates intestinal immune homeostasis.
- Hexavalent chromium promotes malignant transformation via enhanced translation of SUV39H1.
- Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.
- Response to Letter to the Editor Regarding "Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-Small Cell Lung Cancer (NSCLC), a Randomized Controlled Study" in Integrative Cancer Therapies.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.
- Safe discharge on the second postoperative day after major colorectal surgery: a decision-making strategy based on quantitative serological data.